GRAMMATICO, SARA
 Distribuzione geografica
Continente #
NA - Nord America 1.079
EU - Europa 281
AS - Asia 89
OC - Oceania 4
SA - Sud America 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.459
Nazione #
US - Stati Uniti d'America 1.072
IT - Italia 78
SE - Svezia 78
IN - India 49
CN - Cina 33
DE - Germania 28
FI - Finlandia 23
UA - Ucraina 22
BG - Bulgaria 17
GB - Regno Unito 14
CA - Canada 7
BE - Belgio 5
ES - Italia 4
IE - Irlanda 4
TR - Turchia 4
AU - Australia 3
RO - Romania 3
AR - Argentina 2
AT - Austria 1
CL - Cile 1
EU - Europa 1
FR - Francia 1
ID - Indonesia 1
JP - Giappone 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RS - Serbia 1
SC - Seychelles 1
TG - Togo 1
VN - Vietnam 1
Totale 1.459
Città #
Fairfield 204
Chandler 97
Ashburn 88
Woodbridge 80
Houston 63
Seattle 60
Wilmington 60
Cambridge 52
Ann Arbor 47
Princeton 31
Rome 30
Plano 24
Beijing 23
Bremen 20
Sofia 17
Boston 15
Des Moines 15
San Paolo di Civitate 13
Jacksonville 11
Lawrence 11
Millbury 10
San Diego 10
Dearborn 9
Andover 7
Cagliari 6
Norwalk 6
Brussels 5
San Mateo 5
Toronto 5
Falls Church 4
Helsinki 4
Istanbul 4
Milan 4
Redwood City 4
Dublin 3
Fremont 3
Madrid 3
Redmond 3
Cologne 2
Edinburgh 2
Federal 2
Guangzhou 2
Kunming 2
Luton 2
Nanchang 2
New York 2
Prato 2
Southend 2
Sydney 2
Belgrade 1
Boardman 1
Bologna 1
Borgo San Dalmazzo 1
Chicago 1
Coominya 1
Cork 1
Delhi 1
Gurgaon 1
Hanoi 1
Hefei 1
Indiana 1
Jakarta 1
Lomé 1
Melun 1
Montréal 1
Ottawa 1
Phoenix 1
Providence 1
Riva 1
Santi Cosma E Damiano 1
Santiago 1
Secaucus 1
Shenyang 1
Skopje 1
Stolberg 1
Trumbull 1
Vienna 1
Vijayawada 1
Xian 1
Totale 1.108
Nome #
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults 90
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review 88
Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations. 86
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem? 83
Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide 76
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches 76
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma 69
null 69
Corrigendum to "Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept: A case report and literature review" [Leuk. Res. 36 (2012) e199-e201] 68
null 63
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: A 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention 63
Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene 62
Prognostic Factors Associated With Progression of Smoldering Multiple Myeloma to Symptomatic Form 58
null 57
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia 55
null 54
Lineage switch from pro-B acute lymphoid leukemia to acute myeloid leukemia in a case with t(12;17)(p13;q11)/TAF15-ZNF384 rearrangement 53
Efficacy of new drugs as induction treatment before single or tandem autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a single centre experience 51
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study. 50
null 50
CLINICAL OUTCOME AND MONITORING OF MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH THE MLL-ENL GENETICALLY DEFINED ACUTE LYMPHOBLASTIC LEUKEMIA SUBTYPE 38
Management of adult patients with Philadelphia positive acute lymphoblastic leukemia. 23
null 22
Sequential molecular monitoring of chimerism status in two patients transplanted with double unrelated donor umbilical cord blood 21
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. 17
Clinical features and prognostic factors in solitary plasmacytoma 14
null 13
Cyclophosphamide's Addition in Relapsed/Refractory Multiple Myeloma Patients With Biochemical Progression During Lenalidomide-Dexamethasone Treatment 13
Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: Factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteremias 12
. Myeloma; living better and living longer - a look at the advances. 10
Managing treatment-related peripheral neuropathy in patients with multiple myeloma. 8
Solitary Plasmacytoma. 7
Tapentadol PR for pain syndromes in real life patients with hematological malignancy. 6
Totale 1.525
Categoria #
all - tutte 3.383
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.383


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019170 0 0 0 0 0 0 0 0 0 38 71 61
2019/2020387 55 22 8 17 38 41 50 42 40 39 23 12
2020/2021114 14 14 8 5 9 12 1 10 14 12 11 4
2021/2022288 2 17 21 9 38 7 10 21 19 24 58 62
2022/2023331 62 46 21 44 35 45 16 14 39 0 9 0
2023/202492 6 24 3 18 5 19 2 11 1 3 0 0
Totale 1.525